In vivo studies have demonstrated that when a nanogel containing a tumor-specific synthetic long peptide antigen (LPA) and a TLR9 agonist is administered, F4/80+ CD169+ MSMs and F4/80+ CD169− MCMs exhibit cross-presentation capabilities. The gene discussed is SIGLEC1; the disease is neoplasm.